Suppr超能文献

一项关于慢性脑脊髓静脉功能不全血管内治疗的前瞻性开放标签研究。

A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency.

作者信息

Zamboni Paolo, Galeotti Roberto, Menegatti Erica, Malagoni Anna Maria, Gianesini Sergio, Bartolomei Ilaria, Mascoli Francesco, Salvi Fabrizio

机构信息

Vascular Diseases Center, University of Ferrara, Ferrara, Italy.

出版信息

J Vasc Surg. 2009 Dec;50(6):1348-58.e1-3. doi: 10.1016/j.jvs.2009.07.096.

Abstract

OBJECTIVE

Chronic cerebrospinal venous insufficiency (CCSVI) is characterized by combined stenoses of the principal pathways of extracranial venous drainage, including the internal jugular veins (IJVs) and the azygous (AZY) vein, with development of collateral circles and insufficient drainage shown by increased mean transit time in cerebral magnetic resonance (MR) perfusion studies. CCSVI is strongly associated with multiple sclerosis (MS). This study evaluated the safety of CCSVI endovascular treatment and its influence on the clinical outcome of the associated MS.

METHODS

Sixty-five consecutive patients with CCSVI, subdivided by MS clinical course into 35 with relapsing remitting (RR), 20 with secondary progressive (SP), and 10 with primary progressive (PP) MS, underwent percutaneous transluminal angioplasty (PTA). Mean follow-up was 18 months. Vascular outcome measures were postoperative complications, venous pressure, and patency rate. Neurologic outcome measures were cognitive and motor function assessment, rate of MS relapse, rate of MR active positive-enhanced gadolinium MS lesions (Gad+), and quality of life (QOL) MS questionnaire.

RESULTS

Outpatient endovascular treatment of CCSVI was feasible, with a minor and negligible complication rate. Postoperative venous pressure was significantly lower in the IJVs and AZY (P < .001). The risk of restenosis was higher in the IJVs compared with the AZY (patency rate: IJV, 53%; AZY, 96%; odds ratio, 16; 95% confidence interval, 3.5-72.5; P < .0001). CCSVI endovascular treatment significantly improved MS clinical outcome measures, especially in the RR group: the rate of relapse-free patients changed from 27% to 50% postoperatively (P < .001) and of MR Gad+ lesions from 50% to 12% (P < .0001). The Multiple Sclerosis Functional Composite at 1 year improved significantly in RR patients (P < .008) but not in PP or SP. Physical QOL improved significantly in RR (P < .01) and in PP patients (P < .03), with a positive trend in SP (P < .08). Mental QOL showed significant improvement in RR (P < .003) and in PP (P < .01), but not in SP.

CONCLUSIONS

PTA of venous strictures in patients with CCSVI is safe, and especially in patients with RR, the clinical course positively influenced clinical and QOL parameters of the associated MS compared with the preoperative assessment. Restenosis rates are elevated in the IJVs but very promising in the AZY, suggesting the need to improve endovascular techniques in the former. The results of this pilot study warrant a subsequent randomized control study.

摘要

目的

慢性脑脊髓静脉功能不全(CCSVI)的特征是颅外静脉引流主要途径(包括颈内静脉(IJVs)和奇静脉(AZY))合并狭窄,伴有侧支循环形成以及脑磁共振(MR)灌注研究显示平均通过时间延长所提示的引流不足。CCSVI与多发性硬化症(MS)密切相关。本研究评估了CCSVI血管内治疗的安全性及其对相关MS临床结局的影响。

方法

连续65例CCSVI患者,根据MS临床病程分为35例复发缓解型(RR)、20例继发进展型(SP)和10例原发进展型(PP)MS患者,接受经皮腔内血管成形术(PTA)。平均随访18个月。血管结局指标为术后并发症、静脉压和通畅率。神经学结局指标为认知和运动功能评估、MS复发率、MR活性钆增强阳性MS病变(Gad +)率以及MS生活质量(QOL)问卷。

结果

门诊进行CCSVI血管内治疗是可行的,并发症发生率轻微且可忽略不计。术后IJVs和AZY的静脉压显著降低(P <.001)。与AZY相比,IJVs再狭窄风险更高(通畅率:IJVs为53%;AZY为96%;优势比为16;95%置信区间为3.5 - 72.5;P <.0001)。CCSVI血管内治疗显著改善了MS临床结局指标,尤其是在RR组:术后无复发患者比例从27%变为50%(P <.001),MR Gad +病变比例从50%变为12%(P <.0001)。RR患者1年时的多发性硬化功能综合评分显著改善(P <.008),但PP或SP患者未改善。RR组(P <.01)和PP组(P <.03)的身体QOL显著改善,SP组有积极趋势(P <.08)。RR组(P <.003)和PP组(P <.01)的心理QOL显著改善,但SP组未改善。

结论

CCSVI患者静脉狭窄的PTA是安全的,尤其是RR患者,与术前评估相比,其临床病程对相关MS的临床和QOL参数有积极影响。IJVs的再狭窄率较高,但AZY非常有前景,提示需要改进前者的血管内技术。这项初步研究的结果值得后续进行随机对照研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验